HDST-M Stock Overview
HBL - Hadasit Bio-Holdings Ltd operates in the biotechnology industry in Israel.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
HBL - Hadasit Bio-Holdings Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₪0.53 |
| 52 Week High | ₪1.59 |
| 52 Week Low | ₪0.40 |
| Beta | 0.83 |
| 1 Month Change | 8.59% |
| 3 Month Change | n/a |
| 1 Year Change | -64.22% |
| 3 Year Change | -91.54% |
| 5 Year Change | -88.41% |
| Change since IPO | -99.82% |
Recent News & Updates
Shareholder Returns
| HDST-M | IL Biotechs | IL Market | |
|---|---|---|---|
| 7D | 0.2% | -1.7% | 0.3% |
| 1Y | -64.2% | 1.5% | 11.6% |
Return vs Industry: HDST-M underperformed the IL Biotechs industry which returned 1.5% over the past year.
Return vs Market: HDST-M underperformed the IL Market which returned 11.6% over the past year.
Price Volatility
| HDST-M volatility | |
|---|---|
| HDST-M Average Weekly Movement | 20.6% |
| Biotechs Industry Average Movement | 8.2% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in IL Market | 8.4% |
| 10% least volatile stocks in IL Market | 3.1% |
Stable Share Price: HDST-M's share price has been volatile over the past 3 months.
Volatility Over Time: HDST-M's weekly volatility (21%) has been stable over the past year, but is still higher than 75% of IL stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 2 | Yoram Azulai | www.hbl.co.il |
HBL - Hadasit Bio-Holdings Ltd operates in the biotechnology industry in Israel. It operates in the fields of oncology, regenerative medicine, and inflammatory disease. The company develops biological drugs; and plasma RNA biomarkers for colorectal cancer.
HBL - Hadasit Bio-Holdings Ltd Fundamentals Summary
| HDST-M fundamental statistics | |
|---|---|
| Market cap | ₪5.89m |
| Earnings (TTM) | -₪29.19m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.2x
P/E RatioIs HDST-M overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HDST-M income statement (TTM) | |
|---|---|
| Revenue | ₪0 |
| Cost of Revenue | ₪0 |
| Gross Profit | ₪0 |
| Other Expenses | ₪29.19m |
| Earnings | -₪29.19m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.63 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 26.5% |
How did HDST-M perform over the long term?
See historical performance and comparison